117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLC

Bridge City Capital LLC acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 117,374 shares of the biopharmaceutical company's stock, valued at approximately $2,846,000. Bridge City Capital LLC owned 0.10% of Catalyst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in CPRX. Toth Financial Advisory Corp raised its position in Catalyst Pharmaceuticals by 9.7% during the first quarter. Toth Financial Advisory Corp now owns 59,525 shares of the biopharmaceutical company's stock worth $1,443,000 after acquiring an additional 5,275 shares during the last quarter. Wesbanco Bank Inc. acquired a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at $461,000. GAMMA Investing LLC increased its position in Catalyst Pharmaceuticals by 2,959.8% during the 1st quarter. GAMMA Investing LLC now owns 67,682 shares of the biopharmaceutical company's stock worth $1,641,000 after purchasing an additional 65,470 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Catalyst Pharmaceuticals by 7.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 21,419 shares of the biopharmaceutical company's stock worth $447,000 after purchasing an additional 1,402 shares in the last quarter. Finally, Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals in the 4th quarter valued at about $29,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the business's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider now owns 41,081 shares in the company, valued at $1,085,360.02. The trade was a 3.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gary Ingenito sold 44,000 shares of the business's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,627,468.99. This represents a 38.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 247,924 shares of company stock worth $5,879,369. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Price Performance

CPRX stock traded down $1.12 during trading on Thursday, reaching $24.29. 2,007,388 shares of the stock traded hands, compared to its average volume of 1,125,619. The firm has a market capitalization of $2.96 billion, a PE ratio of 20.58, a P/E/G ratio of 3.31 and a beta of 0.72. The business's 50 day moving average price is $23.76 and its 200-day moving average price is $22.83. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.75 and a 52-week high of $26.58.

Wall Street Analysts Forecast Growth

CPRX has been the topic of several analyst reports. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Robert W. Baird raised their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Six research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.